DEA Eases a Key Restriction on Cannabidiol Study

The U.S. Drug Enforcement Administration just removed a particular logjam from the path of research.

Regulatory requirements imposed upon researchers conducting approved clinical trials with cannabidiol, an extract of the marijuana plant, have been reduced, as announced by the United States Drug Enforcement Administration on Wednesday.

Researchers conducting cannabidiol-based experiments are required (as per Title 21 Code of Federal Regulations §1301.18) by the Food and Drug Administration to be registered in order to possess an approved amount of cannabidiol for any detailed study.

Before Wednesday, researchers hoping to expand the range of their experiments—and needed more cannabidiol than originally approved to retain—had to request, in writing, a revision to their DEA registration, which in turn could delay any further research while the adjustment went through an approval procedure that included review by both the DEA and the FDA.

Under the declared changes, a previously registered cannabidiol clinical researcher granted...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.